Invivyd to present data at 2024 american society of clinical oncology (asco) annual meeting and 2024 american transplant congress (atc)

Waltham, mass., may 29, 2024 (globe newswire) -- invivyd, inc. (nasdaq: ivvd), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present preliminary, subset analyses from the canopy phase 3 clinical trial of vyd222 (pemivibart) for pre-exposure prophylaxis of covid-19 at the 2024 american society of clinical oncology (asco) annual meeting and at the 2024 american transplant congress (atc).
ATC Ratings Summary
Quant
ATC Quant Ranking
Sector
Industry
Quant Rating
Quant Score